1-20 of 26
Christos Sotiriou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial

Mattia Rediti, Danai Fimereli, Magdalena Mileva, Zéna Wimana, David Venet, Patrick Flamen, Thomas Guiot, Elisabeth G.E. de Vries, Carolien P. Schröder, Catharina Willemien Menke-van der Houven van Oordt, Marion Maetens, Samira Majjaj, Denis Larsimont, Françoise Rothé, Christos Sotiriou, Géraldine Gebhart
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-24-1007
Published: 06 January 2025
View article titled, Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Open the PDF for Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00

Andrea Joaquin Garcia, Mattia Rediti, David Venet, Samira Majjaj, Roswitha Kammler, Elisabetta Munzone, Lorenzo Gianni, Beat Thürlimann, István Laáng, Marco Colleoni, Sherene Loi, Giuseppe Viale, Meredith M. Regan, Laurence Buisseret, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (23): 4908–4919.
https://doi.org/10.1158/1078-0432.CCR-23-1267
Published: 01 December 2023
View article titled, Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00
Open the PDF for Differential Benefit of Metronomic Chemotherapy Among Triple-Negative Breast Cancer Subtypes Treated in the IBCSG Trial 22–00 in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis

Sara Pizzamiglio, Chiara Maura Ciniselli, Tiziana Triulzi, Chiara Gargiuli, Loris De Cecco, Evandro de Azambuja, Debora Fumagalli, Christos Sotiriou, Nadia Harbeck, Miguel Izquierdo, Paolo Nuciforo, Jens Huober, Vera Cappelletti, Saverio Cinieri, Martine Piccart, Maria Grazia Daidone, Giancarlo Pruneri, Mario Paolo Colombo, Elda Tagliabue, Paolo Verderio, Serena Di Cosimo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6307–6313.
https://doi.org/10.1158/1078-0432.CCR-21-1600
Published: 01 December 2021
View article titled, Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
Open the PDF for Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis in another window
Includes: Supplementary data
Journal Articles

Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer

Ioannis A. Vathiotis, Myrto K. Moutafi, Prajan Divakar, Thazin Nwe Aung, Tao Qing, Aileen Fernandez, Vesal Yaghoobi, Sarra El-Abed, Yingbo Wang, Sebastien Guillaume, Paolo Nuciforo, Jens Huober, Serena Di Cosimo, Sung-Bae Kim, Nadia Harbeck, Henry Gomez, Saba Shafi, Konstantinos N. Syrigos, George Fountzilas, Christos Sotiriou, Lajos Pusztai, Sarah Warren, David L. Rimm
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6156–6163.
https://doi.org/10.1158/1078-0432.CCR-21-2103
Published: 15 November 2021
View article titled, Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer
Open the PDF for Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

David Venet, Mattia Rediti, Marion Maetens, Debora Fumagalli, David N. Brown, Samira Majjaj, Roberto Salgado, Lajos Pusztai, Nadia Harbeck, Sarra El-Abed, Yingbo Wang, Cristina Saura, Henry Gomez, Vladimir Fedorovich Semiglazov, Evandro de Azambuja, Jens Huober, Paolo Nuciforo, Serena Di Cosimo, Martine Piccart, Sherene Loi, Françoise Rothé, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (20): 5607–5618.
https://doi.org/10.1158/1078-0432.CCR-21-1317
Published: 15 October 2021
View article titled, Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
Open the PDF for Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer

François Richard, Samira Majjaj, David Venet, Françoise Rothé, Julien Pingitore, Bram Boeckx, Caterina Marchio, Florian Clatot, François Bertucci, Odette Mariani, Christine Galant, Gert van den Eynden, Roberto Salgado, Elia Biganzoli, Diether Lambrechts, Anne Vincent-Salomon, Giancarlo Pruneri, Denis Larsimont, Christos Sotiriou, Christine Desmedt
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6254–6265.
https://doi.org/10.1158/1078-0432.CCR-20-2268
Published: 01 December 2020
View article titled, Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer
Open the PDF for Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data

Alexios Matikas, Ioannis Zerdes, John Lövrot, François Richard, Christos Sotiriou, Jonas Bergh, Antonios Valachis, Theodoros Foukakis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5717–5726.
https://doi.org/10.1158/1078-0432.CCR-19-1131
Published: 13 September 2019
View article titled, Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data
Open the PDF for Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data in another window
Includes: Supplementary data
Journal Articles

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial

Françoise Rothé, Maria Joao Silva, David Venet, Christine Campbell, Ian Bradburry, Ghizlane Rouas, Evandro de Azambuja, Marion Maetens, Debora Fumagalli, Vanessa Rodrik-Outmezguine, Serena Di Cosimo, Daniela Rosa, Stephen Chia, Andrew Wardley, Takayuki Ueno, Wolfgang Janni, Jens Huober, Jose Baselga, Martine Piccart, Sherene Loi, Christos Sotiriou, Sarah-Jane Dawson, Michail Ignatiadis
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (12): 3581–3588.
https://doi.org/10.1158/1078-0432.CCR-18-2521
Published: 14 June 2019
View article titled, Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Open the PDF for Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial in another window
Includes: Supplementary data
Journal Articles

Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1434.
https://doi.org/10.1158/1078-0432.CCR-18-4267
Published: 15 February 2019
View article titled, Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Journal Articles

HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2

Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, Carlos L. Arteaga
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4323–4334.
https://doi.org/10.1158/1078-0432.CCR-16-2287
Published: 01 August 2017
View article titled, HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Open the PDF for HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2 in another window
Includes: Supplementary data
Journal Articles

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data

Ivana Bozovic-Spasojevic, Dimitrios Zardavas, Sylvain Brohée, Lieveke Ameye, Debora Fumagalli, Felipe Ades, Evandro de Azambuja, Yacine Bareche, Martine Piccart, Marianne Paesmans, Christos Sotiriou
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (11): 2702–2712.
https://doi.org/10.1158/1078-0432.CCR-16-0979
Published: 31 May 2017
View article titled, The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data
Open the PDF for The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data in another window
Includes: Supplementary data
Journal Articles

Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance

Katrien Berns, Amir Sonnenblick, Annemiek Gennissen, Sylvain Brohée, E. Marielle Hijmans, Bastiaan Evers, Debora Fumagalli, Christine Desmedt, Sibylle Loibl, Carsten Denkert, Patrick Neven, Wei Guo, Fan Zhang, Theo A. Knijnenburg, Tjalling Bosse, Michiel S. van der Heijden, Sanne Hindriksen, Wouter Nijkamp, Lodewyk F.A. Wessels, Heikki Joensuu, Gordon B. Mills, Roderick L. Beijersbergen, Christos Sotiriou, René Bernards
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (21): 5238–5248.
https://doi.org/10.1158/1078-0432.CCR-15-2996
Published: 31 October 2016
View article titled, Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance
Open the PDF for Loss of <em>ARID1A</em> Activates <em>ANXA1</em>, which Serves as a Predictive Biomarker for Trastuzumab Resistance in another window
Includes: Supplementary data
Journal Articles

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?

Isabelle Gingras, Christine Desmedt, Michail Ignatiadis, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (21): 4743–4746.
https://doi.org/10.1158/1078-0432.CCR-14-3127
Published: 01 November 2015
View article titled, <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now?
Open the PDF for <em>CCR</em> 20<sup>th</sup> Anniversary Commentary: Gene-Expression Signature in Breast Cancer—Where Did It Start and Where Are We Now? in another window
Includes: Supplementary data
Journal Articles

New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors

Amir Sonnenblick, Debora Fumagalli, Hatem A. Azim, Jr, Christos Sotiriou, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (24): 6242–6246.
https://doi.org/10.1158/1078-0432.CCR-14-1086
Published: 14 December 2014
View article titled, New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T<sub>1a,b</sub>N<sub>0</sub>M<sub>0</sub> Tumors
Open the PDF for New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T<sub>1a,b</sub>N<sub>0</sub>M<sub>0</sub> Tumors in another window
Journal Articles

When will Molecular Fingerprints Dominate Cancer Treatment Selection?

Martine Piccart-Gebhart, Phuong Dinh, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22_Supplement): CN05-03.
Published: 15 August 2014
View article titled, When will Molecular Fingerprints Dominate Cancer Treatment Selection?
Journal Articles

Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer

Fabrice Andre, Maria V. Dieci, Peter Dubsky, Christos Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 28–33.
https://doi.org/10.1158/1078-0432.CCR-11-2701
Published: 02 January 2013
View article titled, Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
Open the PDF for Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer in another window
Journal Articles

Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling

Hatem A. Azim, Jr, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiriou, Sherene Loi
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1341–1351.
https://doi.org/10.1158/1078-0432.CCR-11-2599
Published: 01 March 2012
View article titled, Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling
Open the PDF for Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling in another window
Includes: Supplementary data
Journal Articles

Characterization and Clinical Evaluation of CD10+ Stroma Cells in the Breast Cancer Microenvironment

Christine Desmedt, Samira Majjaj, Naima Kheddoumi, Sandeep K. Singhal, Benjamin Haibe-Kains, Frank El Ouriaghli, Carole Chaboteaux, Stefan Michiels, Françoise Lallemand, Fabrice Journe, Hughes Duvillier, Sherene Loi, John Quackenbush, Sophie Dekoninck, Cédric Blanpain, Laurence Lagneaux, Nawal Houhou, Mauro Delorenzi, Denis Larsimont, Martine Piccart, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (4): 1004–1014.
https://doi.org/10.1158/1078-0432.CCR-11-0383
Published: 14 February 2012
View article titled, Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment
Open the PDF for Characterization and Clinical Evaluation of CD10<sup>+</sup> Stroma Cells in the Breast Cancer Microenvironment in another window
Includes: Supplementary data
Journal Articles

HER-2 as a Target for Breast Cancer Therapy

Michail Ignatiadis, Christine Desmedt, Christos Sotiriou, Evandro de Azambuja, Martine Piccart
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 1848–1852.
https://doi.org/10.1158/1078-0432.CCR-08-1844
Published: 16 March 2009
View article titled, HER-2 as a Target for Breast Cancer Therapy
Open the PDF for HER-2 as a Target for Breast Cancer Therapy in another window
Journal Articles

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

Christine Desmedt, Benjamin Haibe-Kains, Pratyaksha Wirapati, Marc Buyse, Denis Larsimont, Gianluca Bontempi, Mauro Delorenzi, Martine Piccart, Christos Sotiriou
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (16): 5158–5165.
https://doi.org/10.1158/1078-0432.CCR-07-4756
Published: 12 August 2008
View article titled, Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
Open the PDF for Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes in another window
Includes: Supplementary data